This Government Contract opportunity from Department Of Health And Human Services was posted on July 22, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Notice of Intent to Sole Source Serology DV-1-4 EDIII Reagents

Closed

99068Federal

Submission Closed08/06/2026, 09:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325413

New

DIBBS

TEST KIT, CORONAVIRUS D

Solicitation # SPE2DS-27-T-1071

Solicitation SPE2DS-27-T-1071, issued by the DLA Troop Support Medical Supply Chain, is for the procurement of one case of Abbott BinaxNOW COVID-19 Antigen self-test kits for over-the-counter, at-home use. Each case contains 12 kits with 2 tests per kit. The items must be stored between 2-30 degrees Celsius and have a non-extendable shelf life of 12 months, with no more than one month elapsed from the date of manufacture to the date of delivery. Delivery is required within 20 days after receipt of the order, with a final delivery date of October 30, 2026, to the USS IDAHO (SSN 799). The contract mandates strict adherence to Medical Marking Standard No. 1, which supersedes MIL-STD-129, and requires labels to include the contract or lot number and the date of manufacture, expiration, or retest. Packaging must be commercial, utilizing sealed unit containers and suitable exterior shipping containers. Inspection and acceptance will occur at the destination per FAR 52.246-2. Administrative requirements include the use of the Wide Area Workflow system for electronic invoicing and compliance with various FAR and DFARS clauses regarding cybersecurity, the Buy American Act, and the prohibition of covered defense telecommunications equipment. Quotations are due by November 3, 2026.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

CULTURE MEDIUM, THAYER-

Solicitation # SPE2DS-27-T-1066

Solicitation SPE2DS-27-T-1066 is a request for quotations issued by the DLA Troop Support Medical Supply Chain for the procurement of one package of Thayer-Martin Modified (MTM II) Agar culture medium, identified by NSN 6550-01-711-1542. This dark brown, ready-to-use plated medium is specifically designed for the isolation of pathogenic Neisseria from specimens containing mixed flora of bacteria and fungi. The product is delivered in packages of 100 plates and requires strict refrigeration storage between 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) and must not be frozen. The contract mandates a non-extendable shelf life of three months, with a requirement that no more than 14 days elapse between the date of manufacture and the date of delivery to the government. Delivery is set for JBER, Alaska, with a required delivery date of October 27, 2026, under FOB Destination terms. Packaging must be commercial and sealed to prevent damage, with marking adhering to Medical Marking Standard No. 1 and shelf-life labels following MMS1C. Administrative requirements include electronic invoicing via the Wide Area WorkFlow system and compliance with various FAR and DFARS clauses, including the Buy American Act, Berry Amendment, and safeguarding of covered defense information. Evaluation will consider technical data for any alternate products offered and may include HUBZone price evaluation preferences. Inspection and acceptance will occur at the destination.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Supply of ALBAcyte Blood Bank ReagentsThis subcontract involves the manufacture and supply of specialized ALBAcyte blood bank reagents for prime contractors supporting the Department of Veterans Affairs North Texas Health Care System. The scope of work includes the delivery of A1, A2, B, IgG Sensitized, Antibody ID Panels, and C3 Coated RBCs. To ensure product efficacy, the contractor must utilize shipping containers that maintain reagent integrity and adhere to a defined Quality Plan and FDA approval standards. Deliveries are to be made FOB Destination to the Transfusion Medicine Unit located in Dallas, Texas. The contract is categorized under NAICS code 325413 and is managed through the Department of Veterans Affairs Network Contract Office 17.

257-NETWORK Contract Office 17 (36C257)

POSTED

DEADLINE

6550--Blood Bank Reagents

Solicitation # 36C25727Q0065

The Department of Veterans Affairs VA North Texas Health Care System is issuing a Sources Sought Notice to identify qualified vendors capable of providing blood bank reagents for the Transfusion Medicine Unit in Dallas, Texas. These reagents, including ALBAcyte A1, A2, B, IgG Sensitized, Antibody ID Panels, and C3 Coated Red Blood Cells, are essential for manual blood typing and serum antibody detection used in cross-matching blood for transfusions. The anticipated acquisition strategy includes a base year starting May 1, 2027, with four subsequent one-year option periods extending through April 30, 2032. To be considered, vendors must be FDA approved, provide documentation of such approval, and maintain a defined quality plan with adequate supply availability. All shipments must be FOB Destination, and the contractor is responsible for providing appropriate shipping containers. Interested vendors must submit an electronic capability statement in PDF or Word format, including the place of manufacture for all listed reagents, to the designated contract specialist by November 5, 2026, at 9:00 AM CST. This notice is for market research purposes only to determine the appropriate acquisition strategy, such as a small business set-aside, and does not constitute a formal solicitation.

257-NETWORK Contract Office 17 (36C257)

POSTED

DEADLINE

6505--DRESSING, DRAWTEX 4IN X 4IN (VA-27-00014447)

Solicitation # 36C77027Q0015

The Department of Veterans Affairs, National CMOP Office, is conducting market research through a Sources Sought announcement to identify qualified sources for the procurement of Drawtex Dressing, 4in X 4in, packaged as 10ct per box. This action is for market research purposes only and is not a formal solicitation for quotes; therefore, no contract will be awarded based on this specific announcement. The place of performance is located in Ladson, South Carolina, and the primary point of contact is Contract Specialist Claudine Challinor. Interested respondents must submit their information via email by November 3, 2026. Required details include the company's SAM Unique ID Number, business size (Small, Large, SDVOSB, or VOSB), and point of contact information. Specifically, the government is seeking to determine if the respondent is the manufacturer, the manufacturer's product number, and the place of manufacturing. If the respondent is not the manufacturer, they must provide a letter of authorization from the original equipment manufacturer or provide detailed product literature and specifications for alternative products that demonstrate similarities to the Drawtex hydro conductive wound dressing.

National Cmop Office (36C770)

POSTED

DEADLINE

6550--Optilite analyzer reagents

Solicitation # 36C26227Q0052

The Department of Veterans Affairs, Southern Arizona Healthcare System, is soliciting a Firm-Fixed Price Blanket Purchase Agreement under solicitation 36C26227Q0052 for the procurement of FDA-approved reference testing reagents and consumables validated for use on the Optilite analyzer. The scope includes specific items such as Freelite Kappa, Freelite Lambda, and Ceruloplasmin reagents, as well as TENCELL cuvettes and sample cups. To ensure system performance and safety, all materials must be manufactured by Binding Site Laboratories, and substitutions are prohibited. The contract is issued as a full and open competition under NAICS code 325413, with a total estimated period of performance of sixty months, consisting of a base period from November 9, 2026, to November 8, 2027, followed by four one-year option periods. The award will be granted to the responsible offeror whose proposal is most advantageous to the government, based on a technical acceptability review of the Statement of Work and the lowest price. Deliveries are required to be made to various VA Medical Centers across Arizona, California, and New Mexico, with standard orders delivered within four working days of placement. All shipments must be destination-based, with the vendor assuming all shipping costs and adhering to strict packaging standards to prevent damage. Invoicing is handled electronically through the Department of Veterans Affairs Financial Services Center in accordance with the Prompt Payment Act. Quotes must be submitted via email to Contract Specialist Carlos Magana by November 4, 2026.

262-NETWORK Contract Office 22 (36C262)

POSTED

DEADLINE

Supply of i-STAT PT Plus Control Reagent Level 1This subcontract involves the procurement and delivery of i-STAT PT Plus Control Reagent Level 1 for coagulation testing to support prime contractors fulfilling Department of Defense supply contracts. The scope of work requires the delivery of two boxes, each containing ten 1.0 mL units, shipped FOB Destination to a performance location in APO 96260-5479. To ensure quality and safety, all supplied reagents must adhere to Regulation 864.7750 Class II requirements and maintain full compliance with Registration, Listing, Labeling, and Good Manufacturing Practices. This requirement is managed under NAICS code 325413 for the Medical Supply Chain MD Surg FSF agency.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

CONTROL SET, BLOOD CHEM

Solicitation # SPE2DS-27-T-0906

Solicitation SPE2DS-27-T-0906 is a request for quotations from DLA Troop Support for two sets of DXH 500 Series Blood Chemistry Control (NSN 6550-01-688-9090). This assayed whole blood control is used to monitor multi-parameter hematology cell counters and includes abnormal low, normal, and abnormal high components. The items must be stored refrigerated and upright between 2 to 8 degrees Celsius and protected from freezing and overheating. Delivery is required within 20 days after receipt of order, with a required delivery date of October 27, 2026, under FOB Destination terms. The contract imposes strict shelf-life requirements, specifying a non-extendable shelf life of 3 months, with no more than 13 days elapsed from the date of manufacture to the date of delivery. Packaging must be commercial and compliant with RP001 and MIL-STD-2073-1E, while marking must adhere to Medical Marking Standard No. 1. Invoicing is to be processed electronically via the Wide Area Workflow system. This is not a small business set-aside, and the procurement falls under NAICS code 325413. Compliance with the Buy American and Balance of Payments Program and DFARS safeguarding of covered defense information is required.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

CONTROL, BLOOD CHEMISTR

Solicitation # SPE2DS-27-T-0950

Solicitation SPE2DS-27-T-0950 is a Request for Quotations issued by the Department of Defense, DLA Troop Support Medical Supply Chain, for the procurement of two boxes of i-STAT PT Plus Control Reagent Level 1 (NSN 6550-01-728-5703). This reagent is used for coagulation testing and is compatible with the i-STAT PT Plus cartridge and the i-STAT 1 Government Field Kit analyzer. Each box contains ten 1.0 mL units. The required delivery date is October 23, 2026, with a delivery window of 83 days after award. Inspection and acceptance will occur at the destination per FAR 52.246-2. The contract mandates strict quality and storage requirements, including refrigeration between 2 to 8 degrees Celsius and a non-extendable shelf life of 12 months. Items must be delivered within one month of the manufacture date. Packaging must be commercial and adhere to MIL-STD-2073-1E and RP001, with marking compliant with Medical Marking Standard No. 1. Labels must include the contract/lot number and manufacture or expiration dates. The procurement is not a small business set-aside, though a HUBZone price evaluation preference may be applied. Compliance with the Buy American Act and DFARS domestic material restrictions is required, and electronic invoicing must be processed through the Wide Area WorkFlow system.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

BPA - Consumable Supplies for Terumo Trima Accel Blood Collection systems

Solicitation # HT942627QE003

The Defense Health Agency is soliciting quotations to establish a Blanket Purchase Agreement (BPA) for the recurring resupply of consumable products for three Terumo Trima Accel Blood Collection Systems used by the USAISR Combat Casualty Care Research Team 1 in Texas. To maintain FDA approval and satisfy research protocols, the contractor must provide original manufacturer-supplied consumables, including Teruflex 500ml collection bags, Trima Platelet Kits, Isoplate Solution (PAS-F), TSCD Wafers, ACD-A Solution, and 150 mL couplers. This procurement is a 100 percent set-aside for Service-Disabled Veteran-Owned Small Businesses under NAICS 325413. The resulting BPA will have a 60-month ordering period with a total ceiling of 35 million dollars, though some documentation notes a lower limit of 350,000 dollars. Individual call orders are capped at 50,000 dollars, while Government Purchase Card orders are limited to 15,000 dollars. Awards will be made on a Lowest Price Technically Acceptable basis, with technical capability rated as pass or fail. All payment requests and receiving reports must be processed electronically through the Wide Area WorkFlow system. Quotations are due by November 6, 2026, and must be submitted in two separate volumes covering technical capability and pricing.

Army Medical Resources Acq Activity

POSTED

DEADLINE

Custom ArcherDX VariantPlex NGS Target-Enrichment KitsThis subcontract involves the supply of custom-designed Next-Generation Sequencing target-enrichment library preparation kits to support prime contractors on NIH NHLBI projects. The required kits must be manufactured using proprietary ArcherDX VariantPlex Anchored Multiplex PCR chemistry and pre-amplification ligation of unique molecular barcodes. To ensure operational compatibility, all delivered kits must function with Archer Analysis software and Illumina NovaSeq instruments. Managed under the National Institutes of Health Olao within the Department of Health and Human Services, the contract falls under NAICS code 325413. The procurement process began with a posting date of October 22, 2026, and established a response deadline of November 2, 2026.

National Institutes Of Health Olao

POSTED

DEADLINE

6550--VISN Cepheid GeneXpert Testing Supplies Base Plus 3 Op Yr RFQ

Solicitation # 36C24527Q0042

The Department of Veterans Affairs, specifically the VA North Atlantic Health Network (HSA 1.3), is soliciting a firm-fixed-price, Indefinite Delivery/Indefinite Quantity (IDIQ) contract for Cepheid GeneXpert testing supplies. This requirement covers the procurement of FDA-approved reagents, consumables, and service for PCR analyzers to detect various pathogens, including CoV-2, Influenza, RSV, MRSA, and Mycobacterium Tuberculosis. The contract is structured with a base period ending October 31, 2027, and three subsequent one-year option periods extending through October 31, 2030. Deliveries will be made to multiple VA Medical Centers across Maryland, West Virginia, and Washington DC. This acquisition is set aside for HUBZone small businesses. Award will be determined using the Lowest Price Technically Acceptable (LPTA) method, evaluating technical acceptability, delivery performance, past performance, and price, with additional credit given to certified SDVOSB or VOSB offerors. Key contractor requirements include being an authorized distributor, acknowledging orders within 24 hours, and guaranteeing a minimum four-month expiration date on reagents. Additionally, the vendor must provide an emergency plan to deliver replacement supplies within 24 hours if products are found to be defective. Invoices must be submitted electronically, and payments will be processed in accordance with the Prompt Payment Act.

245-NETWORK Contract Office 5 (36C245)

POSTED

7 days ago

DEADLINE

in 7 days

AI Contract Overview

The Centers for Disease Control and Prevention plans to award a sole source firm fixed price contract to the University of North Carolina at Chapel Hill’s Microbiology & Immunology department for the custom production of biotinylated EDIII antigens specific to Zika virus and all four dengue virus serotypes. These antigens are essential for developing and validating serologic assays using streptavidin-based capture and multiplex immunoassay platforms, ensuring high sensitivity and specificity in distinguishing prior infections between dengue and Zika viruses. A HaloTag control antigen is also required to assess nonspecific binding and assay background, providing critical quality control for reagent performance. Commercial alternatives such as whole-virus antigens, full-length envelope proteins, NS1 antigens, and non-biotinylated EDIII constructs were evaluated but rejected due to their inability to meet technical requirements, including excessive cross-reactivity, incompatible tagging systems, inconsistent purity, or mismatched manufacturing methods that would compromise assay reproducibility and data comparability with existing validated protocols. The use of any substitute reagents would necessitate extensive additional optimization, bridging studies, and new validation efforts, leading to significant delays, increased costs, and potential disruption to ongoing laboratory operations. The selected supplier’s ability to produce these antigens with precisely defined sequences, consistent biotinylation, and standardized manufacturing processes is critical to maintaining continuity in the Dengue Branch’s serologic assay strategy. This procurement is authorized under FAR 6.103-1 (SAP) and 41 U.S.C. 1901, allowing for non-competitive award based on the unique technical specifications and absence of viable alternatives. While the notice invites public response, any submissions received by August 6, 2026, at 5 p.m. EST will be considered at the government’s sole discretion to confirm the necessity of sole source procurement, with all correspondence to be directed to [email hidden]. The anticipated performance location is Atlanta, Georgia.

General Info

UNC Chapel Hill to produce custom biotinylated Zika and dengue EDIII antigens under sole source contract for serologic assays.

Agency

Department Of Health And Human Services → Centers For Disease Control And Prevention

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Place of Performance

Atlanta, GA, 30341, USA

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed

PostedJul 22

special-notice

Response DeadlineAug 6

Deadline has passed

Submission Closed

08/06/2026, 09:00:00 PM UTC

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → Centers For Disease Control And Prevention

Contacts1 person available

OfficeAtlanta, GA, 30333, USA

Organization / AgencyDepartment Of Health And Human Services → Centers For Disease Control And Prevention

Office AddressAtlanta, GA, 30333, USA

Contacts

Iris Gonzalez

contact@example.gov

Full Description

The Centers for Disease Control and Prevention intends to award a sole source firm fixed price purchase order/contract to UNIVERSITY OF NORTH CAROLINA -CH Microbiology & Immunology for custom-produced biotinylated EDIII antigens for Zika virus and dengue virus serotypes 1–4 are specifically designed for the CDC flavivirus serologic assay development and validation using streptavidin-based capture and multiplex immunoassay platforms.

The requested HaloTag control antigen also provides a matched control for assessing nonspecific binding, assay background, and reagent-related signal. Published assay validation work using EDIII antigens demonstrated high sensitivity and specificity for distinguishing prior dengue and Zika virus exposure, supporting the technical need for these specialized reagents.

Commercially available whole-virus antigens, full-length envelope proteins, NS1 antigens, non-biotinylated recombinant EDIII antigens, and generic flavivirus assay reagents were considered. However, these alternatives do not meet the Branch’s technical requirements. Whole-virus and full-length flavivirus antigens contain conserved epitopes that can produce substantial cross-reactive antibody binding between dengue and Zika viruses, reducing assay specificity. Non-biotinylated or differently tagged antigens are not suitable substitutes because the current assay workflow depends on biotin–streptavidin capture for stable antigen immobilization, consistent antigen orientation, and reproducible assay conditions. Generic or off-the-shelf antigens also may differ in sequence, tag configuration, purity, lot consistency, or manufacturing method, which could introduce unacceptable variability and compromise comparability with existing validation data and ongoing laboratory protocols.

Use of alternative reagents would require additional optimization, bridging studies, and validation before they could be incorporated into existing workflows. This would delay laboratory testing and research activities, increase costs, and risk generating data that are not comparable with prior or ongoing assay development work. The selected supplier’s custom production of the required biotinylated EDIII and HaloTag control antigens is therefore necessary to maintain reagent consistency, assay performance, and continuity of the Dengue Branch’s serologic assay validation strategy.

This contract action is for supplies/services for which the Government intends to solicit and negotiate with only one source under the authority of Revolutionary FAR Overhaul 6.103-1 (SAP) ; under the authority of 41 U.S.C. 1901, as implemented in FAR subpart 12.102. Interested persons may identify their interest and capability to respond to the requirement or submit proposals.

This notice of intent is not a request for competitive quotations; however, all quotations/responses received within 15 days of the issuance of this notice shall be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to contract specialist at email qsx8@cdc.gov by August 6, 2026 before 5pm EST.